Company news
Starpharma Holdings Limited (ASX:SPL) news
Starpharma Holdings Limited news releases on 6ix. Latest, Dec 10, 2020: VIRALEZE COVID-19 nasal spray to be ready for market Q1CY21
Press releases — page 3
VIRALEZE COVID-19 nasal spray to be ready for market Q1CY21
December 9, 2020
SPL7013 shows potent antiviral activity in RSV
November 18, 2020
Completion of Placement and SPP raises $48.9M in total
October 29, 2020
Starpharma receives $5.7M R&D tax incentive refund
October 20, 2020
Share Purchase Plan offer document
October 6, 2020
Starpharma completes oversubscribed A$45M placement
September 30, 2020
SPL7013 COVID-19 nasal spray virucidal against SARS-CoV-2
September 14, 2020
Starpharma awarded $1M MRFF funding for COVID-19 spray
September 2, 2020
SPL creates slow release soluble DEP remdesivir nanoparticle
August 31, 2020
SPL7013 nasal spray for COVID19 development update
August 25, 2020
Starpharma signs new DEP partnership with Chase Sun
August 16, 2020
DEP irinotecan boosts immuno-oncology in colon cancer models
June 28, 2020
DEP products showcased at AACR 2020
June 22, 2020
DEP lutetium effective in human prostate cancer model
June 17, 2020
VivaGel BV launched in central and eastern Europe
June 16, 2020
DEP irinotecan phase 2 commences after positive phase 1
May 7, 2020
SPL7013 shows significant activity against coronavirus
April 15, 2020
Quarterly Cashflow and Activity Report
April 7, 2020
Okamoto licenses VivaGel antiviral condom in Asian countries
March 3, 2020
VivaGel BV launched in Asia
February 12, 2020
Starpharma receives US$3M milestone from AstraZeneca
February 10, 2020
Quarterly Cashflow Report
January 28, 2020
Commencement of phase 1 trial for AZD0466 utilising DEP
December 29, 2019
Starpharma receives $4.9M R&D tax incentive refund
December 15, 2019
DEP cabazitaxel progresses to phase 2 on positive results
December 9, 2019
AGM - Chairman address and CEO presentation
November 21, 2019
VivaGel condom receives regulatory approval in Europe
November 20, 2019
UK launch of VivaGel BV
November 12, 2019
DEP outperforms Gemzar in human pancreatic cancer model
October 30, 2019
FDA Authorises Clinical Trial with AstraZeneca DEP product
September 25, 2019
DEP irinotecan synergistic with Lynparza in refractory model
September 12, 2019
VivaGel BV regulatory approvals continue in Asia
September 2, 2019
Positive results with Targeted DEP using antibody fragment
August 29, 2019
Promising efficacy signals observed in ongoing DEP trials
August 27, 2019
First Asian Regulatory Approvals Received for VivaGel BV
August 14, 2019
Starpharma commences phase 1/2 DEP irinotecan trial
August 7, 2019
VivaGel BV launched in Europe
June 27, 2019
Starpharma signs second oncology agreement with AstraZeneca
June 2, 2019
DEP irinotecan combination outperforms in colon cancel model
May 24, 2019
First VivaGel BV launch globally in Australia by Aspen
April 16, 2019
Starpharma receives $4.0M R&D tax incentive refund
March 11, 2019
Interim Report and Half-Yearly Financial Results
February 26, 2019
Response to ASX Aware Letter
January 7, 2019
VivaGel condom receives final regulatory approval in Japan
January 1, 2019
US FDA requests further data for VivaGel BV approval
December 27, 2018
US VivaGel BV licensed for A$142M milestones plus royalties
December 19, 2018
DEP products outperform in human pancreatic cancer model
November 16, 2018
Starpharma Investor Presentation for Citi Conference
October 16, 2018
DEP irinotecan outperforms in pancreatic cancer model
September 5, 2018
AstraZeneca DEP Bcl2/xL inhibitors show compelling efficacy
August 31, 2018